Next Article in Journal
Molecular Mode of Action of TRAIL Receptor Agonists—Common Principles and Their Translational Exploitation
Previous Article in Journal
Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study
Article Menu
Issue 7 (July) cover image

Export Article

Open AccessCommunication

Prostate Cancer Development Is Not Affected by Statin Use in Patients with Elevated PSA Levels

Department of Urology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, De Boelelaan 1117, 1081HV Amsterdam, The Netherlands
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(7), 953; https://doi.org/10.3390/cancers11070953
Received: 28 May 2019 / Revised: 4 July 2019 / Accepted: 5 July 2019 / Published: 7 July 2019
  |  
PDF [835 KB, uploaded 8 July 2019]
  |  

Abstract

Background: The role of statins in prostate cancer (PCa) remains unclear. Conflicting evidence has been found concerning risk reduction with the use of statins on biochemical recurrence (BCR). In this study, we evaluated whether statin use decreases the incidence of advanced PCa in males with elevated prostate-specific antigen (PSA; ≥4.0 ng/mL) levels and determined whether statin use reduces the risk of BCR after radical prostatectomy (RP). Methods: Patients visiting the outpatient urology clinic of the VU Medical Center between 2006 and 2018 with elevated PSA were retrospectively analyzed. Biochemical recurrence after RP was defined as a PSA level of ≥0.2 ng/mL (measured twice). Results: A total of 1566 patients were included, of which 1122 (72%) were diagnosed with PCa. At the time of diagnosis, 252 patients (23%) used statins compared to 83 patients (19%) in the non-malignancy group (p = 0.10). No differences were found in the use of statins between the different risk groups. No correlation was found between the risk of BCR after RP and the use of statins in the total (p = 0.20), the intermediate-risk group (p = 0.63) or the high-risk group (p = 0.14). Conclusion: The use of statins does not affect PCa development/progression in patients with elevated PSA levels, nor the development of BCR after RP. View Full-Text
Keywords: statin; biochemical recurrence; biochemically recurrent; prostate cancer statin; biochemical recurrence; biochemically recurrent; prostate cancer
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Meijer, D.; van Moorselaar, R.J.A.; Vis, A.N.; Bijnsdorp, I.V. Prostate Cancer Development Is Not Affected by Statin Use in Patients with Elevated PSA Levels. Cancers 2019, 11, 953.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top